Actively Recruiting
Characterize Behavioral Early Signs of Psychotic Disorders in Children With 22q11.2 Deletion Syndrome Aged 4 to 13 Years
Led by Hôpital le Vinatier · Updated on 2025-07-30
80
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the early behavioral signs that may signal the onset of psychotic disorders in children with 22q11.2 deletion syndrome (22q11.2DS), a common genetic condition linked to an increased risk of schizophrenia. This study aims to better understand social cognitive processes and behavioral changes that could lead to psychotic symptoms in children aged 4 to 13 years, including those without developmental diseases for comparison. The study involves two groups: children with 22q11.2DS and children without developmental disorders, both aged 4 to 13 years. Participants will complete neuropsychological tests, questionnaires, and experimental tasks to assess attention, behavior, gaze direction, and facial expression recognition. These activities include well-established batteries such as TEA-Ch, Rey's Tangled Lines Test, and NEPSY II, performed during a single study visit. During participation, children will undergo various assessments including anxiety-related emotional disorder screening and facial expression recognition tasks. Researchers will also measure sustained hearing attention, reaction times, and other cognitive functions. The study does not involve any drug treatments and participation includes behavioral testing and questionnaires completed by the children's legal representatives. The entire study visit occurs on one day, and the research will continue through September 2026 to gather comprehensive data from enrolled children.
CONDITIONS
Brief Title
Understanding of Psychotic Disorders in Children With 22q11.2DS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of 22q11.2 deletion syndrome or no developmental disease
- Aged from 4 to 13 years old
- Ability to understand and communicate in French
You will not qualify if you...
- Diagnosis of intellectual deficiency according to DSM 5 criteria
- Use of medication for a physical condition that might affect brain function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants complete neuropsychological testing, questionnaires, and experimental tasks to assess behavioral and cognitive functions related to psychotic disorders.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Hopital Vinatier
Lyon, Auvergne-Rhône-Alpes, France, 69678
Actively Recruiting
Research Team
C
Caroline DEMILY, MD PH
V
Véronique VIAL
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here